Mechanical Ventilation and Survival in Patients With Advanced Dementia in Medicare Advantage

Medicare Advantage (MA) cares for an increasing proportion of traditional Medicare (TM) patients although, the association of MA on low-value care among hospitalized patients is uncertain. We sought to determine whether invasive mechanical ventilation (IMV) use or mortality differs among hospitalize...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of pain and symptom management Ročník 63; číslo 6; s. 1006 - 1013
Hlavní autori: Sullivan, Donald R., Gozalo, Pedro, Bunker, Jennifer, Teno, Joan M.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Elsevier Inc 01.06.2022
Elsevier Limited
Predmet:
Aged
Aged, 80 and over
Anesthesia
care quality
Concentration
Dementia
Dementia - therapy
Enrollments
Female
Functional impairment
Home health care
Hospitalization
Humans
Male
Mechanical ventilation
Medicare
Medicare advantage
Medicare Part C
Mortality
Mortality rates
Nursing homes
Pain Medicine
Patients
Respiration, Artificial
Retrospective Studies
serious illness
United States
Ventilation
United States
Medicare advantage
mechanical ventilation
Medicare
care quality
serious illness
Dementia
ISSN:0885-3924, 1873-6513, 1873-6513
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Medicare Advantage (MA) cares for an increasing proportion of traditional Medicare (TM) patients although, the association of MA on low-value care among hospitalized patients is uncertain. We sought to determine whether invasive mechanical ventilation (IMV) use or mortality differs among hospitalized patients with advanced dementia (AD) enrolled in MA vs. TM and the influence of hospital MA concentration. Retrospective cohort of hospitalized Medicare patients from 2016 to 2017 who were ≥66 years old with AD (n=147,153) and had a hospitalization with an assessment completed during a nursing home stay ≤120 days prior to that hospitalization indicating AD and severe cognitive/functional impairment. MA enrollment was ascertained at hospitalization; IMV use and 30- and 365-day mortality were determined via Medicare data. Multivariable logistic regression models clustered by hospital were used. Among hospitalized Medicare patients with AD, 27,253 (19%) were enrolled in MA, mean age was 84 (95% CI: 83.9–84.0) and 92,736 (63%) were female. Enrollment in MA was associated with increased IMV use (Adjusted Odds Ratio(AOR)=1.11, 95% CI: 1.04–1.18), 30- (Adjusted Hazard Ratio(AHR)=1.09, 95% CI: 1.05–1.12) and 365-day mortality (AHR=1.12, 95% CI: 1.08–1.16) compared to TM. Use of IMV was not different based on concentration of MA at the hospital level. MA may reduce hospitalizations, however, once hospitalized, patients with AD enrolled in MA experience higher rates of IMV use and worse 30- and 365-day mortality compared to TM patients. Higher hospital concentration of MA did not reduce use of IMV. MA may not offer significant benefits in reducing low-value care among patients hospitalized with serious illness, questioning the benefits of this care model.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0885-3924
1873-6513
1873-6513
DOI:10.1016/j.jpainsymman.2022.02.011